DelveInsight’s, “Osteoarthritis Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 110+ ...
Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food and Drug Administration (FDA) has accepted ...
Treating people who are at high risk of rheumatoid arthritis (RA) can delay the onset of the disease for several years, with ...
WASHINGTON — Investigational treatments aimed specifically at reducing pain in knee osteoarthritis (OA) are moving forward in parallel with disease-modifying approaches. “We still have very few ...
Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of CLK/DYRK kinases, announced today that ...
People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.
Starting metformin is associated with a lower risk of developing osteoarthritis over 11 years of follow-up in a study comparing twins who initiated the drug with those who did not.
Scientists at Stanford Medicine have discovered a treatment that can reverse cartilage loss in aging joints and even prevent arthritis after knee injuries. By blocking a protein linked to aging, the ...
The University of Liverpool, in partnership with AKL Research and Development Ltd, is to lead on a clinical trial to test a potential new drug treatment for osteoarthritis. Osteoarthritis (OA) is the ...
Researchers find drug could delay rheumatoid arthritis by years - Rheumatoid arthritis affects about 400,000 people aged 16 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback